Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDF in Chinese CHB with Advanced Fibrosis/Cirrhosis
NCT02224456Phase 4Completed
- Sponsor
- GSK
- Start
- Mar 2015
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir disoproxil fumarate in hepatitis B (HBV), sponsored by GSK. Primary endpoints: Incidence Rate of Newly Diagnosed Hepatocellular Carcinoma (HCC) at 240 weeks and Percentage of Participants With Disease Progression at 240 weeks. Started Mar 2015; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT02224456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02224456.